We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals
News

Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals

Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals
News

Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nuvo Research to Receive US$6.0 Million of Milestone Payments from Pliaglis® E.U. Approvals"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Nuvo Research Inc. has announced that Galderma S.A. (Galderma), a global company dedicated to dermatology has received its first three Pliaglis marketing licenses from E.U. countries.

These licenses entitle Nuvo to receive a total of US$6.0 million of milestone payments from its worldwide Pliaglis marketing partner, Galderma.

The milestone payments are due on the earlier of the launch of Pliaglis in the approved countries or 6 months from the date of marketing approval.

The payments are expected in December 2012 (US$5.0 million) and January 2013 (US$1.0 million).

Galderma has advised Nuvo that it expects to launch Pliaglis in the E.U. and other territories in the first half of 2013.

Nuvo previously filed a Marketing Authorization Application (MAA) for the approval of Pliaglis in 16 E.U. countries using the European Decentralized Procedure and on May 4, 2012 received a positive recommendation that Pliaglis is approvable for the indication of producing local dermal anesthesia on intact skin in adults prior to superficial dermatological procedures.

The regulatory process then entered its final phase during which individual countries issue marketing licenses that allow Pliaglis to be marketed in each country.

Nuvo expects to receive marketing licenses from the other E.U. countries over the next 12 months.

"We are extremely pleased that Pliaglis is in the process of being approved in a number of E.U. countries and that Nuvo is receiving a substantial regulatory milestone payment as a result," said Dr. Bradley Galer, President of Nuvo's Pain Group.

Dr. Galer continued, "The upcoming launch of Pliaglis will mean that Nuvo will have 3 growing sources of revenue from globally commercialized topical pain products."

Advertisement